RVMDW
MaterialsRevolution Medicines Inc - Warrants (17/12/2026)
$5.61+0.26 (+4.86%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RVMDW Today?
No stock-specific AI insight has been generated for RVMDW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.07$6.23
$5.61
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume69K
Avg Volume (10D)—
Shares Outstanding—
RVMDW News
25 articles- RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewYahoo Finance·May 7, 2026
- Revolution Medicines, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Revolution Medicines Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerGlobeNewswire Inc.·May 6, 2026
- Royalty Pharma Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressYahoo Finance·May 6, 2026
- How FDA Expanded Access for Daraxonrasib and Phase 3 Survival Data At Revolution Medicines (RVMD) Has Changed Its Investment StoryYahoo Finance·May 6, 2026
- Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B OpportunityYahoo Finance·May 2, 2026
- Revolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This StockYahoo Finance·May 2, 2026
- Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsYahoo Finance·Apr 30, 2026
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026Yahoo Finance·Apr 29, 2026
- Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute EmergesYahoo Finance·Apr 29, 2026
- Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?Pharmavoice·Apr 29, 2026
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug TrialMotley Fool·Apr 28, 2026
- Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.Yahoo Finance·Apr 28, 2026
- Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its ValueYahoo Finance·Apr 28, 2026
- Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical UpdatesYahoo Finance·Apr 28, 2026
- Revolution Medicines Trial Updates Spark Fresh Interest In RAS Focused PipelineYahoo Finance·Apr 28, 2026
- Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It SeemsMotley Fool·Apr 27, 2026
- SCHA vs. ISCB Comes Down to Sector Tilt and Your Drawdown ToleranceThe Motley Fool·Apr 25, 2026
- Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual MeetingYahoo Finance·Apr 21, 2026
- Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 19, 2026
- IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?Benzinga·Apr 19, 2026
- Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior NotesGlobeNewswire Inc.·Apr 15, 2026
- Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: AnalystBenzinga·Mar 25, 2026
All 25 articles loaded
Price Data
Open$5.17
Previous Close$5.35
Day High$5.38
Day Low$4.61
52 Week High$6.23
52 Week Low$0.07
52-Week Range
$0.07$6.23
$5.61
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume69K
Avg Volume (10D)—
Shares Outstanding—
About Revolution Medicines Inc - Warrants (17/12/2026)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—